Provista Life Sciences Announces the Opening of Its Clinical
Laboratory – Provista Diagnostics (PDx)
PHOENIX (Business Wire EON/PRWEB ) April 24, 2007 --
Provista Life Sciences LLC (PLS) announced today the opening of its
clinical laboratory operations, Provista Diagnostics, LLC (PDx). PDx is
a wholly owned subsidiary of PLS. The laboratory will provide the
necessary analytical support to advance the clinical trials and
commercialization efforts of the first three diagnostic technology
companies under PLS’ management umbrella: GW
Medical Technologies’ LymPro®
Test for the early detection of Alzheimer’
disease, Biomarker Technologies’ BT Test™
for the early detection of breast cancer and RCP Diagnostics’
RCP-Dx Test™ for the detection of women’s
estrogen associated cancers: ovarian, uterine, cervical and breast.
“Provista Life Sciences is a biotechnology
commercialization organization that identifies and acquires the rights
to promising medical diagnostics technologies. We then unify their
respective operational and business development activities under our
management company,” says PLS CEO William
Gartner. “Provista Diagnostics will provide a
complementary and critical addition to our diagnostic development
strategy supporting the further development of our existing women’s
oncology and Alzheimer’s diagnostics. It will
also serve as our conduit for early market introduction of these Tests.”
PDx has the exclusive U.S. rights to these tests and plans to introduce
these diagnostic services to the public under a direct-to-consumer and
health care provider access plan. The test services will provide
consumers and their respective health care providers with a means to
make earlier and better informed decisions regarding their personal
health care needs related to their respective cancer or Alzheimer’s
disease.
“We are advancing the development and
commercialization of diagnostic technologies that have the potential for
early disease state recognition as well as therapeutic drug development
and efficacy monitoring,” says Donald Weber,
Vice President of Strategic Alliances for PLS. Weber stated that PDx
expects to commercially introduce the BT and RCP-Dx Test Services this
summer followed by the LymPro Test Service in early 2008.
“These are extremely important blood
diagnostics,” says Weber. “Early
detection has been recognized as a key component, if not the most
important to cancer survival, and to the treatment of Alzheimer’s
disease. Our goal is to make sure these test services are available to
the public as soon as feasibly possible.”
About Provista Diagnostic LLC
Provista Diagnostics was established in 2007 and is a CLIA registered
laboratory focused on the development and commercialization of three
breakthrough blood diagnostic for the detection of Breast Cancer, Women’s
Estrogen Related Cancers (Ovarian, Uterine, Cervical, and Breast) and
Alzheimer’s disease (AD). All three
diagnostics will be initially released as adjunctive tests to be used in
conjunction with or separate from existing diagnostic procedures such as
imaging techniques, PET Scans, etc. Each such diagnostic is intended to
assist the individual’s physician or health
care provider to better diagnose the respective disease covered by these
tests and provide a more accurate and earlier detection of these
devastating diseases. For more information, visit the company’s
web site at www.ProvistaDx.com
or call 602-840-8333.
Provista Life Sciences’ Background
Provista Life Sciences was established in 2006 as a biotechnology
mezzanine development organization that provides the scientific and
operating management resources to rapidly advance the development and
introduction of novel diagnostics technologies into the domestic and
global marketplace. For more information, visit the company’s
web site at www.provistals.com
or call 602-224-5500.
See the original story at: http://eon.businesswire.com/releases/provista/diagnostic/prweb520321.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U2luZy1UaGlyLUVtcHQtUHJvZi1NYWduLVplcm8=
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
